Jill Wechsler

Jill Wechsler is a veteran reporter specializing in federal health care and pharmaceutical issues.


Medicare Part D plans control drug spending

September 04, 2012

The Medicare Part D prescription drug program has emerged as the poster child for how private plans can control costs while providing quality care. Even critics of health insurers acknowledge that the drug benefit has been a success.

FDA user fee legislation speeds drug approvals, addresses shortages, counterfeits

August 01, 2012

The passage of the FDA Safety and Innovation Act will support innovation, answer the current shortages, and even regulate mobile applications.

CER studies will shape coverage decisions

July 25, 2012

To reduce the money spent on treatments that don't work, health plans and payers are examining closely how Comparative Effectiveness Research (CER) can steer patients and providers to more appropriate care. This approach is gaining momentum from the Patient Centered Outcomes Research Institute (PCORI), which is poised to distribute some $120 million in coming months—and nearly $400 million in 2013—to launch a range of CER projects.

Payers seek more comparative research documenting value and affordability of high-cost therapies

July 01, 2012

While scientists and biomedical researchers at the recent meeting of the American Society of Clinical Oncology (ASCO) applauded encouraging data on dozens of breakthrough cancer therapies, analysts pondered strategies for convincing payers to cover the new life-saving drugs.

Health reform survives

June 28, 2012

In a complex decision, a slim majority of the Supreme Court upheld the constitutionality of the Affordable Care Act.

Congress moves promptly to finalize FDA user fees

June 19, 2012

House and Senate leaders announced final agreement June 18 on legislation that authorizes industry user fees to support FDA regulatory programs.